SUPPLEMENT
FY2025 — Five-year review
FY2025PDF · 4 pages104 KB
FIVE-YEAR REVIEWfor the year ended 30 June 2025 -- 1 of 4 -- Normalised five-year review R million Year ended 30 June Compound growth % 2021 2022 2023 2024 2025 Statement of financial position – normalised Total assets 1 870 043 1 999 800 2 295 274 2 366 815 2 586 538 8 Core lending advances 1 208 468 1 311 441 1 511 037 1 597 898 1 699 002 9 Gross advances before impairments 1 274 052 1 382 058 1 590 447 1 665 706 1 803 827 9 Total impairments 50 618 47 734 51 072 54 165 55 188 2 Gross advances (net of impairments) 1 223 434 1 334 324 1 539 375 1 611 541 1 748 639 9 Stage 3/NPLs 60 705 50 886 57 432 67 840 74 484 5 Deposits 1 542 078 1 655 972 1 923 103 2 003 151 2 181 874 9 Capital and reserves attributable to equityholders of the group 151 647 165 642 181 451 195 664 217 418 9 Income statement – normalised Net interest income before impairment of advances 64 511 67 856 78 615 86 105 91 231 9 Impairment charge (13 660) (7 080) (10 949) (12 555) (14 044) 1 Total non-interest revenue 44 980 48 362 52 393 55 295 58 463 7 Operational non-interest revenue 43 548 46 856 51 900 52 873 55 522 6 Share of profit of associates and joint ventures after tax 1 432 1 506 493 2 422 2 941 20 Operating expenses (57 342) (61 024) (67 320) (74 405) (75 998) 7 Earnings attributable to ordinary equityholders of the group 26 551 32 663 36 634 37 988 41 824 12 Key ratios – normalised ROE (%) 18.4 20.6 21.1 20.1 20.2 ROA (%) 1.41 1.69 1.71 1.63 1.69 Cost-to-income ratio (%) 52.4 52.5 51.4 52.6 50.8 Credit loss ratio (%) – core lending advances 1.10 0.56 0.78 0.81 0.85 Stage 3/NPLs as a % of core lending advances 5.02 3.88 3.80 4.25 4.38 Diversity ratio (%) 41.1 41.6 40.0 39.1 39.1 Share statistics – normalised Price earnings ratio (times) 11.3 10.7 10.5 11.4 10.1 Price-to-book ratio (times) 2.0 2.1 2.1 2.2 1.9 Market capitalisation 300 612 349 864 384 250 431 370 424 582 9 Closing share price (cents) 5 359 6 237 6 850 7 690 7 569 9 01 FIRSTRAND GROUP NORMALISED FIVE-YEAR REVIEW -- 2 of 4 -- Normalised five-year review continued R million Year ended 30 June Compound growth % 2021 2022 2023 2024 2025 Exchange rates $/R – Closing 14.26 16.41 18.84 18.22 17.78 – Average 15.33 15.19 17.73 18.71 18.15 £/R – Closing 19.72 19.95 23.95 22.99 24.36 – Average 20.66 20.21 21.31 23.55 23.49 Statement of financial position ($ million)* – normalised Total assets 131 139 121 865 121 830 129 902 145 475 3 Core lending advances 84 745 79 917 80 204 87 700 95 567 3 Gross advances before impairments 89 344 84 220 84 419 91 422 101 463 3 Total impairments 3 550 2 909 2 711 2 973 3 104 (3) Gross advances (net of impairments) 85 795 81 312 81 708 88 449 98 359 3 Stage 3/NPLs 4 257 3 101 3 048 3 723 4 190 – Deposits 108 140 100 912 102 076 109 942 122 715 3 Capital and reserves attributable to equityholders of the group 10 634 10 094 9 631 10 739 12 228 4 Income statement ($ million)# – normalised Net interest income before impairment of advances 4 208 4 467 4 434 4 602 5 027 5 Impairment charge (891) (466) (618) (671) (774) (3) Total non-interest revenue 2 934 3 184 2 955 2 955 3 221 2 Operational non-interest revenue 2 841 3 085 2 927 2 826 3 059 2 Share of profit of associates and joint ventures after tax 93 99 28 129 162 15 Operating expenses (3 741) (4 017) (3 797) (3 977) (4 187) 3 Earnings attributable to ordinary equityholders of the group 1 732 2 150 2 066 2 030 2 304 7 Statement of financial position (£ million)* – normalised Total assets 94 830 100 241 95 836 102 950 106 180 3 Core lending advances 61 281 65 736 63 091 69 504 69 737 3 Gross advances before impairments 64 607 69 276 66 407 72 454 74 039 3 Total impairments 2 567 2 393 2 132 2 356 2 265 (3) Advances (net of impairments) 62 040 66 883 64 275 70 097 71 774 4 Stage 3/NPLs 3 078 2 551 2 398 2 951 3 057 – Deposits 78 199 83 006 80 297 87 131 89 568 3 Capital and reserves attributable to equityholders of the group 7 690 8 303 7 576 8 511 8 925 4 Income statement (£ million)# – normalised Net interest income before impairment of advances 3 123 3 358 3 689 3 656 3 884 6 Impairment charge (661) (350) (514) (533) (598) (2) Total non-interest revenue 2 177 2 393 2 459 2 348 2 489 3 Operational non-interest revenue 2 108 2 318 2 435 2 245 2 364 3 Share of profit of associates and joint ventures after tax 69 75 23 103 125 16 Operating expenses (2 776) (3 019) (3 159) (3 159) (3 235) 4 Earnings attributable to ordinary equityholders of the group 1 285 1 616 1 719 1 613 1 781 8 * The statement of financial position is converted using the closing rates as disclosed for each reporting year. # The income statement is converted using the average rate as disclosed for each reporting year. 02 FIRSTRAND GROUP NORMALISED FIVE-YEAR REVIEW -- 3 of 4 -- www.firstrand.co.za -- 4 of 4 --